Nov 16,2022

Diabetes Care App BeatO Raises $33 Million In Series B Funding Led By Lightrock India

BeatO, on November 16, announced to have raised $33 million in a series B round of funding that was led by Lightrock India with participation from HealthQuad, Flipkart and the company’s existing investors.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Feb 07,2023

Newel Health Awarded $2.5M Research Grant from The Michael J. Fox Foundation for Further Development of Soturi, an Innovative Digital Therapeutic Solution for People Living with Parkinson’s Disease

Newel Health announced today that it was selected to receive a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) [MJFF-022711] to advance the research and development of Soturi, a Digital Therapeutic (DTx) solution for personalized medication and treatment plan optimization for people with Parkinson’s disease.

FUNDING GRANT
View Analyst & Ambassador Comments
Go to original news
Feb 07,2023

Third Culture Capital Leads Latest Funding Round for Ciba Health

Third Culture Capital (3CC), a seed-stage venture capital firm investing in diverse, minority, and "Third Culture" led startups revolutionizing healthcare innovation and modern care delivery, led the latest funding round of Ciba Health, a global digital therapeutics company and cutting-edge technology platform addressing and reversing chronic disease conditions. The funding round closed on Dec. 31, 2022 at an undisclosed amount. Ciba Health’s program individually tailors chronic care to address root causes of an individual's symptoms, and allows patients to choose their own team of providers from various locations, languages, and cultural and/or economic backgrounds that will remain dedicated providers for them throughout the program. Ciba Health also provides patients with internet devices and other tools to address access gaps in global healthcare more deeply.

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
Feb 16,2023

VA awards OxfordVR $500,000 in Mission Daybreak grand challenge to reduce Veteran suicides

The U.S. Department of Veterans Affairs has named OxfordVR as a winner in Mission Daybreak — a $20 million challenge designed to help VA develop new suicide prevention strategies for Veterans. As a third-place award winner, OxfordVR, which recently came under the BehaVR umbrella, will receive $500,000 to further support the company's work in developing virtual reality (VR) solutions to address mental and behavioral health challenges in support of Veterans.

FUNDING GRANT

#virtual reality

View Analyst & Ambassador Comments
Go to original news
Feb 20,2023 TOP STORY

Axena Health raises $25M to support pelvic floor digital therapeutic

Axena Health, which makes a women's pelvic health digital therapeutic, announced it had raised a $25 million Series A investment from XA IM Alts. Axena offers the Leva Pelvic Health System, a prescription digital therapeutic aimed at treating urinary incontinence and chronic fecal incontinence in women. The system, which has received FDA 510(k) clearance, includes a vaginal motion sensor that connects to an app, guiding users through pelvic floor muscle training. According to an Axena spokesperson, the company acquired the system from Renovia, which developed and commercialized Leva before it shut down last year.

FUNDING SERIES A

#pdt

View Analyst & Ambassador Comments
Go to original news
Mar 23,2017

Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced the pricing of an underwritten public offering of 18,000,000 shares of its common stock at a price to the public of $1.25 per share. The gross proceeds to Tandem from this offering are expected to be $22.5 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Tandem. 

FUNDING POST-IPO EQUITY
View Analyst & Ambassador Comments
Go to original news
Oct 20,2016

Propeller Health Completes $21.5 Million Financing to Transform Respiratory Disease through Digitally-Guided Therapy

Propeller Health, the leading digital solution for respiratory medicine, today announced the closing of its $21.5 million Series C financing. The funding round includes new investors 3M Ventures, S.R. One, Limited and Hikma Ventures, and existing investors Safeguard Scientifics and Social Capital. Proceeds will be used to expand Propeller’s digitally-guided therapy platform and modernize the management of respiratory disease.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Feb 01,2023

CSIT Awards Curio Digital Therapeutics Maternal and Infant Health R&D Seed Grant

The Commission on Science, Innovation and Technology (CSIT) Board awarded Curio Digital Therapeutics a $75,000 grant to accelerate the development of technologies, products, and services that support maternal and child wellbeing in New Jersey. Curio was selected alongside 16 other highly promising startups for a grand total of $1.275 million in combined grants. The grants were awarded through CSIT’s Maternal and Infant Health Research & Development (R&D) Grant Program, which launched last June.

FUNDING GRANT
View Analyst & Ambassador Comments
Go to original news
Dec 13,2022

BehaVR and OxfordVR Combine and Raise Series B to Create Largest VR Delivery Platform for Evidence-Based Digital Therapeutics

Virtual reality mental and behavioral health companies BehaVR and OxfordVR today announced their merger, supported by an initial $13 million in Series B funding led by Optum Ventures and Oxford Science Enterprises, with participation from Confluent Health, Accenture Ventures, Chrysalis Ventures and Thornton Capital.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Jan 10,2020

Virta Health Raises $93 Million to Combat the $400B Type 2 Diabetes Epidemic and Expand Diabetes Reversal to Millions

Virta Health, the first company with a treatment to sustainably reverse type 2 diabetes (T2D) without medications or surgery, today announced that it has raised $93 million in Series C funding to combat the growing prevalence of T2D, bringing the total equity funding to $166 million. Funding will enable investing in growth to meet the demand for T2D reversal from employers, health plans and government, as existing approaches to treating the illness over the past decade have not improved population-level treatment outcomes.

FUNDING SERIES C
View Analyst & Ambassador Comments
Go to original news
Subscribe to FUNDING